Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
Nuvation Bio (NYSE: NUVB) will report fourth quarter and full year 2025 financial results and provide a business update on March 2, 2026 at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) will report fourth quarter and full year 2025 financial results and provide a business update on March 2, 2026 at 4:30 p.m. ET. The company will host a conference call and live webcast; registration and replay will be available on Nuvation Bio's Investor Relations website for 90 days.
Details
News Market Reaction – NUVB
On Feb 18, the first trading day after this news, NUVB closed 1.87% below the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Earnings call date
- March 2, 2026
- Q4 and full-year 2025 results conference call
- Earnings call time
- 4:30 p.m. ET
- Scheduled start of conference call and webcast
- Replay availability
- 90 days
- Archived recording available on company website
Historical Context
-
Phase 2 SIGMA trial converted to pivotal Phase 3 with larger enrollment.
-
Preliminary 4Q25/2025 results, IBTROZI revenue, cash and 2026 outlook shared.
-
Eisai taletrectinib licensing with upfront, milestones and tiered royalties.
-
J.P. Morgan Healthcare Conference presentation and webcast details announced.
-
Seven innovative drugs included in China’s 2025 NRDL effective Jan 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-868, a BD2-selective BET inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-2-2026-302688141.html
SOURCE Nuvation Bio Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.